PEB
data caveat$153M—
Pacific Edge
Oncology
Cxbladder — urine-based mRNA test for bladder cancer detection, monitoring and surveillance
Data HealthFiling4C overdue · Dec 202580dTrials4 of 4 active · stale enrollment
No cash data on fileFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—Market Cap
$153M
Burn Rate
—
Shares Outstanding
1.0B
Pipeline Assets
4
Latest Insight(1)
4 Mar 2026substantial_holderChange in substantial holding
Changed·Harbour Asset Management Limited·9.957%
3M Price
PEB.ASX$0.150-7.7% 3M
Low $0.145High $0.220
Pipeline Assets (4)
Cxbladder Triagebladder cancer
ApprovedCxbladder Detectbladder cancer
ApprovedCxbladder Monitorbladder cancer recurrence
ApprovedCxbladder Resolvebladder cancer
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Substantial Holders (5%+ threshold)
2 noticesarrow_drop_downHarbour Asset Management Limited
9.96%2026-03-04
arrow_drop_downHarbour Asset Management Limited
9.96%2026-03-04
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
8 approved drugs357 competitor trialsPhase 2+ · Non-ASX
Bladder Cancer320 active trials
11 Ph476 Ph314 Ph2/3158 Ph261 Ph1/PHASE2
Bladder Cancer Recurrence37 active trials
2 Ph413 Ph32 Ph2/315 Ph25 Ph1/PHASE2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
Catalysts (5)· 3 upcoming · 2 past
SpeculativeremoveMed30 May 2026
SpeculativeremoveMed1 Jan 2027
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
0/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
Clinical Trials(7)
4 activeClinicalTrials.gov ↗
RecruitingOBSERVATIONALEnrollment stale · 902d
Cxbladder urine test
Detection and Risk Stratification in Veterans Presenting With Microscopic Hematuria
Urothelial Carcinoma
18 Years – 89 Years
Primary endpoint To validate the performance characteristics of Cxbladder Triage Plus in a US cohort which will consist of subjects with a recent history of hematuria and are referred to urology and scheduled for cystoscopy for the evaluation of hematuria.
RecruitingOBSERVATIONALEnrollment stale · 1414d
CxBladder Monitor/Monitor+
Longitudinal Bladder Cancer Study for Tumour Recurrence
Urothelial Bladder Cancer
18 Years+
Primary endpoint To clinically validate the performance characteristics of CxBladder Monitor/Monitor+
NARecruitingEnrollment stale · 1083d
Urinalysis
Bladder Cancer Screening Trial
Bladder Cancer · Urothelial Carcinoma · Hematuria +1 more
50 Years+
Primary endpoint Incidence of Bladder cancer (BCa)
Announcements(6)
description
Quarterly ActivitiesPS
Q4 26 Test Volumes Rise with Medicare Policy Momentum9 Apr 2026
1962KB